药物性肝损伤发病机制研究进展*

doi:10.3969/j.issn.1672-5069.2014.06.027

摘要/Abstract

摘要： 药物的肝脏毒性是欧美国家导致急性肝衰竭的重要原因。Kaplowitz提出的以特异性“上游”事件和非特异性“下游”事件为基础的DILI（Drug induced liver injury, DILI）发病机制,为进一步开展DILI机制的研究提供了明确的方向。目前已知,DILI的发生机制复杂,涉及药物代谢、线粒体功能损伤、免疫反应、信号转导、遗传和环境等多个方面。DILI的发生和进展可能是多重因素综合作用的结果。

关键词: 药物性肝损伤, 发病机制, 线粒体功能损伤

Abstract: DILI is the most important cause of acute liver failure in the U.S. The emerging concept of drug-specific “upstream” events that cause initial hepatocyte injury and less specific“downstream” events described by Kaplowitz,which provides clear direction for further DILI mechanism research. Currently,it’s well-know that the mechanism of DILI is complex,involving drug metabolism, mitochondrial dysfunction,immune response,signal transduction,genetic and environmental et al. Progression of DILI may be the result of the combined effects of multiple factors.

Key words: Drug-induced liver injury, pathogenesis

明雅南综述, 刘晓琳茅益民审校. 药物性肝损伤发病机制研究进展^*[J]. 实用肝脏病杂志, 2014, 17(6): 657-661.

Ming Yanan, Liu Xiaolin, MaoYimin. The pathogenesis of drug-induced liver injury（DILI）[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(6): 657-661.

参考文献

[1] Larson AM,Polson J,Fontana RJ,et al. Acetaminophen-induced acute liver failure:results of a United States multicenter,prospective study. Hepatology,2005,42:1364-1372.
[2] Senior JR. Drug hepatotoxicity from a regulatory perspective. Clin Liver Dis,2007,11:507-524.
[3] Kuehn BM. Dietary supplement linked to cases of acute hepatitis. JAMA,2013,310（17）:1784.
[4] Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov,2005,4:489-499.
[5] Russmann S,Jetter A,Kullak-Ublick GA. Pharmacogenetics of drug-induced liver injury. Hepatology,2010,52（2）:748-761.
[6] Lammert C,Bjornsson E,Niklasson A,et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology,2010,51:615-620.
[7] Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis ,2007,11:525-548.
[8] Hsin-Tien Ho,Teng-Hsu Wang,Cheng-Huei Hsiong,et al. The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity. Pharmacogenet Genomics,2013,23（4）:200-7.
[9] Mitchell R. McGill,C. David Williams,Yuchao Xie et al. Acetaminophen-induced Liver Injury in Rats and Mice:Comparison of Protein Adducts,Mitochondrial Dysfunction,and Oxidative Stress in the Mechanism of Toxicity.Toxicol Appl Pharmacol,2012,264（3）:387-394.
[10] Jaeschke H,Cover C,and Bajt ML. Role of caspases in acetaminophen-induced liver injury. Life Sci. 2006 Mar 6;78（15）:1670-6. Epub 2005 Oct 13. Adv Exp Med Biol,2001,500:663-73.
[11] Qiu Y,Benet LZ,and Burlingame AL . Identification of hepatic protein targets of the reactive metabolites of the non-hepatotoxic regioisomer of acetaminophen,3-hydroxyacetanilide,in the mouse in vivo using two-dimensional gel electrophoresis and mass spectrometry. Adv Exp Med Biol,2001,500:663-73.
[12] Kon K,Kim JS,Jaeschke H,et al. Mitochondrial permeability transition in acetaminophen-induced necrotic and apoptotic cell death to cultured mouse hepatocytes. Hepatology,2004,40:1170-1179
[13] Jaeschke H,Lemasters JJ .Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology,2003,125:1246-1257.
[14] Bajt ML,Farhood A,Lemasters JJ,et al. Mitochondrial bax translocation accelerates DNA fragmentation and cell necrosis in amurine model of acetaminophen hepatotoxicity. J Pharmacol Exp Ther,2008,324:8-14.
[15] UziD,BardaL,ScaiewiczV,et al.CHOP is a critical regular of acemitophen-induced hepatoxicity.Journal of Hepatology,2013,59:495-503
[16] Fisher JE,McKenzie TJ,Role of Kupffer cells and toll-like receptor 4 in acetaminophen-induced acute liver failure. J Surg Res,2013,180（1）:147-55.
[17] Liu ZX,Govindarajan S,Okamoto S,et al. NK cells cause liver injury and facilitate the induction of T cell mediated immunity to a viral liver infection. J Immunol,2000,164:6480-6486
[18] Lawson JA,Farhood A,Hopper RD,et al. The hepatic inflammatory response after acetaminophen overdose:role of neutrophils. Toxicol Sci,2000,54:509-516.
[19] Cover C,Liu J,Farhood A,Malle E,et al. Pathophysiological role of the acute inflammatory response during acetaminophen hepatotoxicity. Toxicol Appl Pharmacol,2006,216（1）:98-107.
[20] Liu ZX,Govindarajan S,Okamoto S,et al. NK cells cause liver injury and facilitate the induction of T cell mediated immunity to a viral liver infection. J Immunol,2000,164:6480-6486.
[21] Martin-Murphy BV,Kominsky DJ,Orlicky DJ,et al. Increased susceptibility of natural killer T-cell-deficient mice to acetaminophen-induced liver injury. Hepatology,2013,57（4）:1575-84.
[22] Daly AK,Donaldson PT,Bhatnagar P,et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet,2009,41（7）:816-9.
[23] Monshi MM,Faulkner L,Gibson A,et al. Human leukocyte antigen （HLA）-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology,2013,57（2）:727-39.
[24] Patin E,Harmant C,Kidd K K,et al. Sub-saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Hum Mutat,2006,27:720.
[25] Lin J J,Han C-Y,Link B K,Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians,Blacks,Hispanics,and Whites:application to metabolic epidemiology. Am J Human Genet,1993,52:827-834.
[26] Kim S H,Kim S H,Bahn J W,et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics,2009,10:1767-1779.
[27] Chen M,Borlak J,Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology,2013,58（1）:388-96.
[28] Jane F. Maddox,Chidozie J. Amuzie. et al. Bacterial-and Viral-Induced Inflammation Increases Sensitivity to Acetaminophen Hepatotoxicity. Journal of Toxicology and Environmental Health,2010 ,73:58-73.
[29] M. Isabel Lucena. Raul J. Andrade. Neil Kaplowitz. et al. Phenotypic Characterization of Idiosyncratic DrugInduced Liver Injury:The Influence of Age and Sex. Hepatology,2009,49（6）:2001-9.
[30] Stefan Russmann,Alexander Jetter,Gerd A. Kullak-Ublick Pharmacogenetics of Drug-Induced Liver Injury Hepatology,2010,52（2）:748-61.
[31] Daly AK,Donaldson PT,Bhatnagar P,et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet,2009,41（7）:816-9
[32] Kindmark A,Jawaid A,Harbron CG,et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J,2008,8:186-195.
[33] Tang N,Deng R,Wang Y,et al. GSTM1 and GSTT1 null polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury:a meta-analysis. Int J Tuberc Lung Dis,2013,17（1）:17-25
[34] Dávila-Fajardo CL,Swen JJ,Cabeza Barrera J,et al.Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. Pharmacogenomics,2013,14（1）:63-73.
[35] Pande JN,Singh SP,Khilnani GC,et al. Risk factors for hepatotoxicity from antituberculosis drugs:a case-control study.Thorax,1996,51:132-136.
[36] Garcia-Closas M,Hein DW,Silverman D, et al. A single nucleotide polymorphism tags variation in the arylamineN-acetyltransferase 2 phenotype in populations of European background. Pharmacogenet Genomics,2011,21:231-236.
[37] Ho HT,Wang TH,Hsiong CH,et al. The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity. Pharmacogenetics and Genomics,2013,23:200-207.
[38] Anup Ramachandran,Mitchell R. McGill,Yuchao Xie,et al. Receptor Interacting Protein Kinase 3 Is a Critical Early Mediator of Acetaminophen-induced Hepatocyte Necrosis in MiceHepatology,2013,58（6）:2099-108.
[39] Patel SJ,Milwid JM,King KR,et al. Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure. Nat Biotechnol,2012,30（2）:179-83.

药物性肝损伤发病机制研究进展^*

The pathogenesis of drug-induced liver injury（DILI）

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[2]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.
[3]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[4]	吴欣, 郭杨志, 杜霄壤, 吴孟晋, 朱云, 冯兴中. 75例中药诱导的肝损伤患者临床特征分析*[J]. 实用肝脏病杂志, 2019, 22(5): 668-671.
[5]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[6]	刘立伟,赵新颜. 药物性肝损伤临床与组织病理学特点[J]. 实用肝脏病杂志, 2019, 22(2): 160-163.
[7]	黄春洋,单晶,廖慧钰,黄云丽,韩莹,张小丹,杜晓菲,任美欣,边新渠,刘燕敏. 甲基强的松龙治疗药物性肝损伤患者临床及实验室特点分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 208-211.
[8]	吴秀欣,张惠勇,张凯. 抗结核药物所致肝损伤患者血浆MiRNA-4284水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 212-215.
[9]	宋芳娇,朱冰,吕飒,田华,王海波,辛绍杰,游绍莉. 314例药物性肝衰竭患者临床特征分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 216-219.
[10]	胡虎兰综述, 朱梦飞, 施军平审校. 慢性乙型肝炎合并非酒精性脂肪性肝病临床研究进展^*[J]. 实用肝脏病杂志, 2019, 22(1): 149-152.
[11]	孙文静, 陈东风. UCAM和Maria诊断标准用于评估1352例中国人药物性肝损伤文献分析[J]. 实用肝脏病杂志, 2018, 21(6): 881-884.
[12]	夏庚综述, 祁飞, 杨晋辉审校. 自身免疫性肝炎诱发因素研究进展[J]. 实用肝脏病杂志, 2018, 21(6): 983-986.
[13]	崔瑞冰, 阎明. 腹水原因解析[J]. 实用肝脏病杂志, 2018, 21(5): 657-660.
[14]	李越, 丁惠国. 乳糜性腹水诊治现状^*[J]. 实用肝脏病杂志, 2018, 21(5): 665-668.
[15]	佟欣, 樊华. 双环醇治疗胃癌化疗所致肝损伤患者肝功能指标的变化[J]. 实用肝脏病杂志, 2018, 21(4): 625-626.